Prices are updated after-hours

Professional, Scientific, and Technical Services 0

Cyclo Therapeutics Inc - Class A

CYTH | $1.19 -0.83% -0.84% 57K

(0.0% 1d) (-20.5% 1m) (52.1% 1y) (-3.3% 2d) (-3.3% 3d) (-6.5% 7d) (93.73% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 34,171,731
https://www.cyclotherapeutics.com
Sec Filling | Patents | 8 employees

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

cholesterol genetic alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Panbela Therapeutics Inc

PBLA | $0.4895 -6.31% 66K

Professional, Scientific, and T...

(0.0% 1d) (-34.4% 1m) (-97.0% 1y) (0.0% 2d) (-19.2% 3d) (-22.2% 7d) (363.69% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 2,376,454
http://www.sunbiopharma.com/
Sec Filling | Patents | 6 employees

(US) Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

cancer treatment pancreatic

add to watch list Paper trade email alert is off

Seer Inc - Class A

SEER | $1.67 -4.57% -4.79% 670K

Professional, Scientific, and T...

(0.0% 1d) (-12.6% 1m) (-56.0% 1y) (0.0% 2d) (-1.8% 3d) (-7.3% 7d) (77.25% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 101,416,112
https://seer.bio
Sec Filling | Patents | 60 employees

Seek Inc. is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. The Company's Proteograph is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. The Company's designed the Proteograph to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution broadly available to life sciences researchers.

housing

add to watch list Paper trade email alert is off

ImmunoPrecise Antibodies Ltd

IPA | $1.24 0.0% 150K

Professional, Scientific, and T...

(0.0% 1d) (-10.0% 1m) (-59.1% 1y) (0.0% 2d) (-0.8% 3d) (1.6% 7d) (155.05% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 32,630,922
http://www.immunoprecise.com/
Sec Filling | Patents | 2021 employees

(CA) IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company's therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes.

covid antibody

add to watch list Paper trade email alert is off

Singular Genomics Systems Inc

OMIC | $0.3925 0.93% 0.92% 120K

Professional, Scientific, and T...

(0.0% 1d) (-18.8% 1m) (-61.9% 1y) (0.0% 2d) (0.0% 3d) (6.1% 7d) (-53.63% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 29,016,959
https://singulargenomics.com
Sec Filling | Patents | 138 employees

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.

t-cell

add to watch list Paper trade email alert is off

Synaptogenix Inc

SNPX | $4.33 -7.08% -7.62% 30K

Professional, Scientific, and T...

(0.0% 1d) (2132.0% 1m) (346.4% 1y) (0.0% 2d) (-9.8% 3d) (-2.0% 7d) (-75.49% volume)
Earnings Calendar:
Market Cap: $ 117,487,401

Sec Filling | Patents | 5 employees

synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.

add to watch list Paper trade email alert is off

Janux Therapeutics Inc

JANX | $48.69 -0.33% -0.33% 670K

Professional, Scientific, and T...

(0.0% 1d) (22.2% 1m) (216.0% 1y) (0.0% 2d) (1.5% 3d) (-6.1% 7d) (8.98% volume)
Earnings Calendar: 2024-03-08
Market Cap: $ 2,515,328,321
https://www.januxrx.com
Sec Filling | Patents | 16 employees

(US) Janux Therapeutics is developing safe, effective novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets. The Janux TRACTr development pipeline targets multiple solid tumor indications, including colorectal, gastroesophageal, prostrate, NSCLC, triple negative breast, and ovarian cancers. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response. Combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling has the potential to significantly improve safety, expand the therapeutic dosing window, and maximize patient responses. Janux was founded in the Avalon Ventures accelerator, COI Pharmaceuticals, Inc., in San Diego.

cancer ovarian cancer

add to watch list Paper trade email alert is off

UpHealth Inc

UPH | $0.3 9.13% 0.0% 350K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-82.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3.3% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 5,332,649
https://www.gigcapital2.com
Sec Filling | Patents | 2 employees

(United States) GigCapital Global is a Private-to-Public Equity investment group, sponsoring and operating Special Purpose Acquisition Companies ('SPAC', also known as Blank-Check companies). Founded in 2017 by Dr. Avi Katz, the GigCapital Group and its sponsored SPACs are led by an affiliated team of technology industry experts, deploying a unique Mentor-Investors™ methodology to partner with exceptional privately-held and U.S. and non-U.S. public technology companies led by dedicated, innovative entrepreneurs. The GigCapital Group companies offer financial, operational and executive mentoring to U.S. and global private, and non-U.S. public companies, in order to accelerate their path from inception and as a privately-held entity into the growth-stage as a publicly traded company in the U.S. The partnership of the GigCapital Group with these companies continues through an organic and roll-up strategy growth post the transition to a public company.

msa acquisitions spac blank check

add to watch list Paper trade email alert is off

Acurx Pharmaceuticals LLC

ACXP | $2.02 -5.16% -5.45% 94K

Professional, Scientific, and T...

(0.0% 1d) (-2.4% 1m) (-33.4% 1y) (-5.6% 2d) (-5.6% 3d) (22.9% 7d) (-34.38% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 31,829,346
https://www.acurxpharma.com
Sec Filling | Patents | 3 employees

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).

injection

add to watch list Paper trade email alert is off

Alzamend Neuro Inc

ALZN | $0.6894 -0.23% -0.23% 28K

Professional, Scientific, and T...

(0.0% 1d) (-35.2% 1m) (13.3% 1y) (-1.4% 2d) (-1.4% 3d) (-8.2% 7d) (3.58% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 4,734,004
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

Convey Holding Parent Inc

CNVY 4 | $10.51 0.0%

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-0.5% 3d) (0.0% 7d) (239.48% volume)
Earnings Calendar:
Market Cap: $ 769,270,737
https://www.conveyhealthsolutions.com
Sec Filling | Patents | 3000 employees

Convey is a specialized healthcare technology and services company that is committed to providing clients with healthcare-specific, compliant member support solutions utilizing technology, engagement, and analytics. Convey's administrative solutions for government-sponsored health plans help to optimize member interactions, ensure compliance, and support end-to-end Medicare processes. By combining its purpose-built technology platforms with dedicated and flexible business process solutions, Convey creates better business results and better healthcare consumer experiences on behalf of business customers and partners. Convey's clients include some of the nation's leading health insurance plans and pharmacy benefit management firms. Convey's healthcare-focused teams help millions of Americans navigate the complex Medicare Advantage and Part D landscape.

optical ycombinator

add to watch list Paper trade email alert is off

iSpecimen Inc

ISPC | $0.2915 -30.76% -44.43% 2.8M

Professional, Scientific, and T...

(0.0% 1d) (5.5% 1m) (-83.3% 1y) (0.0% 2d) (38.1% 3d) (37.4% 7d) (948.27% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 2,732,721

Sec Filling | Patents | 75 employees

headquartered in lexington, ma, ispecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. the privately held company has developed the ispecimen marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. researchers easily and compliantly gain access to specimens to drive scientific discovery. partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. and ultimately, healthcare advances for all.

add to watch list Paper trade email alert is off

Lyell Immunopharma Inc

LYEL | $2.24 -3.86% -4.02% 1.1M

Professional, Scientific, and T...

(0.0% 1d) (9.3% 1m) (-3.5% 1y) (0.0% 2d) (-6.3% 3d) (-7.1% 7d) (4.71% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 569,175,737
https://lyell.com
Sec Filling | Patents | 189 employees

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington.

genetic t-cell renewable

add to watch list Paper trade email alert is off

Miromatrix Medical Inc

MIRO | $3.39 3.25% 630K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (142.1% 1y) (0.0% 2d) (0.0% 3d) (0.6% 7d) (273.61% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 92,951,183

Sec Filling | Patents | 37 employees

miromatrix medical inc. is a life science company that has a novel and proprietary technology to remove cells from, or decellularize, organs and tissues from animal and human sources, facilitating the creation of numerous products, including the potential of fully biological transplantable human organs.

t-cell

add to watch list Paper trade email alert is off

Monte Rosa Therapeutics Inc

GLUE | $5.84 -1.35% -1.37% 110K

Professional, Scientific, and T...

(0.0% 1d) (-22.9% 1m) (2.3% 1y) (0.0% 2d) (0.9% 3d) (-11.0% 7d) (5.5% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 292,876,000
https://www.monterosatx.com
Sec Filling | Patents | 60 employees

Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.

drug discovery profitable computational machine learning

add to watch list Paper trade email alert is off

Graphite Bio Inc

GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (14.0% 1y) (0.0% 2d) (-2.8% 3d) (0.0% 7d) (-33.57% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 190,434,748
https://graphitebio.com
Sec Filling | Patents | 27 employees

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

gene therapies

add to watch list Paper trade email alert is off

Mister Car Wash Inc

MCW 4 | $6.71 0.6% 0.0% 1.2M

Professional, Scientific, and T...

(0.0% 1d) (-11.1% 1m) (-22.4% 1y) (0.0% 2d) (3.4% 3d) (1.8% 7d) (-22.81% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 2,132,673,400
https://mistercarwash.com
Sec Filling | Patents | 4625 employees

Headquartered in Tucson, Arizona, Mister Car Wash operates over 340 car washes nationwide. The Mister Car Wash brand is anchored in quality, friendliness and a commitment to creating memorable customer experiences. Mister Car Wash’s people are what make it successful and allow it to achieve these high standards. Mister Car Wash continues to focus on recruiting and retaining top talent, developing best-in-class training programs and investing in employee benefits to cultivate a positive company culture.

brands

add to watch list Paper trade email alert is off

Alpha Teknova Inc

TKNO | $2.09 3.98% 3.83% 2.8K

Professional, Scientific, and T...

(0.0% 1d) (-20.9% 1m) (-2.9% 1y) (0.0% 2d) (-5.2% 3d) (-17.4% 7d) (-62.87% volume)
Earnings Calendar: 2024-03-11
Market Cap: $ 85,320,879
https://www.teknova.com
Sec Filling | Patents | 193 employees

Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale across all stages of development, including commercialization.

diagnostics gene therapies t-cell

add to watch list Paper trade email alert is off

Aerovate Therapeutics Inc

AVTE M | $21.86 1.2% 1.19% 220K

Professional, Scientific, and T...

(0.0% 1d) (-15.2% 1m) (13.0% 1y) (0.0% 2d) (0.0% 3d) (-12.8% 7d) (64.62% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 609,019,600
https://www.aerovatetx.com
Sec Filling | Patents | 2021 employees

Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.

treatment

add to watch list Paper trade email alert is off

Finch Therapeutics Group Inc

FNCH | $2.205 -6.57% -7.03% 30K

Professional, Scientific, and T...

(0.0% 1d) (-14.2% 1m) (-84.3% 1y) (0.0% 2d) (-11.1% 3d) (-0.2% 7d) (-76.8% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 3,540,707
https://finchtherapeutics.com
Sec Filling | Patents | n/a employees

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

hepatitis gastrointestinal treatment injection

add to watch list Paper trade email alert is off